Insider sale details
Yeleswaram Krishnaswamy, Chief Development Officer at Rapport Therapeutics, Inc. (NASDAQ: RAPP), sold 20,225 shares of the company’s common stock on April 17, 2026. The disposition generated proceeds totalling $808,844, with the shares transacted at prices ranging from $39.90 to $40.38. Following the sale, Mr. Krishnaswamy directly holds 246,426 shares of Rapport common stock.
The sales were carried out under a Rule 10b5-1 trading plan that Mr. Krishnaswamy established on December 10, 2025. On the date of this report, Rapport’s share price has moved to $36.95. The company’s market capitalization is reported at $1.78 billion and the stock is up 258% over the past year.
Valuation and analyst context
According to InvestingPro analysis cited in the company’s reporting, the stock currently appears overvalued versus its Fair Value estimate. The InvestingPro platform is noted to provide additional ProTips and a suite of financial metrics for investors preparing for Rapport’s May 7 earnings report.
Clinical progress for RAP-219
Rapport Therapeutics has reported promising clinical data from its Phase 2a trial of RAP-219, an investigational therapy for epilepsy. During the trial follow-up period, patients experienced a median 90% reduction in seizures during weeks 9-12 and a 59% reduction in weeks 13-16 compared with baseline measurements. The company plans to present these results at the 2026 American Academy of Neurology Annual Meeting.
In response to the Phase 2a data, Rapport announced plans to initiate Phase 3 trials for RAP-219 in the second quarter of 2026, moving the program forward ahead of the company’s original schedule. The planned Phase 3 studies are expected to enroll approximately 320 patients per study and will test various dosages over a 14-week treatment period.
Market reaction and broker outlook
Following the accelerated development timeline and the release of fiscal 2025 results, three brokerages - Truist Securities, Stifel, and Jones Trading - each reiterated a Buy rating on Rapport Therapeutics. The firms published price targets of $44.00, $56.00, and $50.00, respectively.
What to watch next
Key near-term events include Rapport’s May 7 earnings report and the company’s planned transition to Phase 3 testing for RAP-219 in the second quarter. Investors monitoring valuation metrics, clinical readouts, and upcoming corporate disclosures will likely use those data points to reassess the company’s outlook.
This article reports the company-disclosed transaction, clinical results, analyst ratings, and planned trial details without adding external commentary or speculation.